DrugPatentWatch Database Preview
ONZETRA XSAIL Drug Profile
or, see our see our flat-rate plans
When do Onzetra Xsail patents expire, and when can generic versions of Onzetra Xsail launch?
This drug has two hundred and thirty-three patent family members in twenty-eight countries.
The generic ingredient in ONZETRA XSAIL is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
Summary for ONZETRA XSAIL
| International Patents: | 233 |
| US Patents: | 13 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 81 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,887 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ONZETRA XSAIL at DailyMed |
Synonyms for ONZETRA XSAIL
| (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide |
| (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide # |
| 1-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide |
| 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide |
| 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide |
| 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methyl-methanesulfonamide |
| 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide |
| 103628-46-2 |
| 103628-48-4 (succinate) |
| 1H-Indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl- |
| 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide |
| 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole -5-methanesulphonamide |
| 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide |
| 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide |
| 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide |
| 628S462 |
| 8R78F6L9VO |
| AB0016356 |
| AB00698285_14 |
| AB00698285_15 |
| AB00698285-12 |
| AB00698285-13 |
| AC1L1K6B |
| AJ-08373 |
| AKOS015894924 |
| Ambap103628-46-2 |
| AN-5271 |
| API0004291 |
| AVP 825 |
| AVP-825 |
| AVP825 |
| BDBM50005835 |
| BIDD:GT0248 |
| BRD-K50938287-001-01-7 |
| BRN 6930870 |
| BSPBio_002304 |
| C07319 |
| C14H21N3O2S |
| CAS-103628-46-2 |
| CCG-230331 |
| CHEBI:10650 |
| CHEMBL128 |
| D00451 |
| D0Z6UC |
| DB00669 |
| DR001144 |
| DSSTox_CID_3628 |
| DSSTox_GSID_23628 |
| DSSTox_RID_77118 |
| DTXSID4023628 |
| FT-0631027 |
| GR 43175 |
| GR 43175X |
| GR-43175 |
| GR43175 |
| GTPL54 |
| HE291385 |
| HMS2231B21 |
| HMS3369A05 |
| HSDB 7742 |
| I06-0076 |
| Imigran (TN) |
| Imigran Recovery |
| Imitrex (TN) |
| Imitrex Oral |
| Imitrex, Imigran ,Treximet |
| J-001014 |
| KB-217141 |
| KQKPFRSPSRPDEB-UHFFFAOYSA-N |
| KS-1116 |
| L000584 |
| LS-83175 |
| MCULE-3991948648 |
| MLS001195659 |
| MLS001304742 |
| MolPort-002-885-863 |
| NCGC00095838-01 |
| NCGC00095838-02 |
| NCGC00095838-03 |
| NCGC00095838-04 |
| NP101 |
| O262 |
| SBI-0206837.P001 |
| SC-18016 |
| SCHEMBL1482 |
| SMR000596517 |
| SPECTRUM1505372 |
| STL451003 |
| Sumatran |
| sumatriptan |
| Sumatriptan (JAN/USP/INN) |
| Sumatriptan [USP:INN:BAN] |
| Sumatriptanum |
| Sumatriptanum [INN-Latin] |
| Sumax |
| Tox21_111528 |
| Tox21_111528_1 |
| UNII-8R78F6L9VO |
| Zecuity |
| Zembrace SymTouch |
| ZINC14360 |
US Patents and Regulatory Information for ONZETRA XSAIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avanir Pharms | ONZETRA XSAIL | sumatriptan succinate | POWDER;INHALATION | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Avanir Pharms | ONZETRA XSAIL | sumatriptan succinate | POWDER;INHALATION | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Avanir Pharms | ONZETRA XSAIL | sumatriptan succinate | POWDER;INHALATION | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Avanir Pharms | ONZETRA XSAIL | sumatriptan succinate | POWDER;INHALATION | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
Non-Orange Book US Patents for ONZETRA XSAIL
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,841,337 | Breath-actuated nasal delivery device | ➤ Try a Free Trial |
| 9,144,652 | Powder delivery devices | ➤ Try a Free Trial |
| 7,481,218 | Nasal devices | ➤ Try a Free Trial |
| 8,522,778 | Nasal devices | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
or, see our see our flat-rate plans
International Patents for ONZETRA XSAIL
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 2013027724 | ➤ Try a Free Trial |
| Slovenia | 1161274 | ➤ Try a Free Trial |
| South Africa | 200309660 | ➤ Try a Free Trial |
| Mexico | PA01008849 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
